Impact of Tumour Burden on Chemotherapy-Induced Nausea and Vomiting
Author Information
Author(s): TJ Hursti, E Avall-Lundqvist, S B6rjeson, M Fredrikson, CJ First, G Steineck, C Peterson
Primary Institution: Karolinska Institute
Hypothesis
How does residual tumour burden after cytoreductive surgery relate to the occurrence of nausea and vomiting in ovarian cancer patients receiving chemotherapy?
Conclusion
Patients with larger residual tumour burdens experienced more nausea and vomiting after chemotherapy, especially older patients.
Supporting Evidence
- Patients with large tumour burden reported more delayed emesis, especially on days 2-7.
- Older patients (>55 years) with large tumour burden had higher occurrences of nausea.
- Anti-emetic treatment with dexamethasone was a predictor for no delayed emesis.
Takeaway
If you have a bigger tumor left after surgery, you might feel more sick after chemotherapy, especially if you're older.
Methodology
The study involved 101 chemotherapy-naive ovarian cancer patients who self-reported nausea and vomiting for 15 days after their first chemotherapy course.
Potential Biases
Potential biases may arise from self-reported data and the exclusion of patients with severe concurrent diseases.
Limitations
The study did not primarily aim to identify predictors of delayed emesis, and most previous studies were not designed for this purpose.
Participant Demographics
Median age was 54 years, with a range from 18 to 76 years; 68% of patients with large tumour burden were over 55 years old.
Statistical Information
P-Value
0.003
Confidence Interval
1.1-1.9
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website